Background And Aims: Dengue is a mosquito-borne viral disease that frequently causes seasonal outbreaks in Bangladesh, particularly during the monsoon months from June to September. Recent outbreaks have shown significant shifts in clinical manifestations, including changes in the timeframe and serotype mixing. This study focused on the clinical and hematological profiles of patients during the 2022 outbreak, which was notably severe.
Methods: This quantitative cross-sectional study at Dhaka Medical College and Hospital classified 67 dengue-positive patients as having dengue fever (DF), dengue fever with warning signs (DFWS), and severe dengue (SD). Fisher's exact test, Pearson's chi-squared test, and Wilcoxon rank-sum test were conducted for statistical analysis using the R software (version 4.2), with significance established at < 0.05.
Results: Predominantly male patients (76%) aged 21-40 (63%) and middle-class patients from Dhaka (57%) formed the majority. Most patients (45%) lacked a regular drainage system. Laboratory tests showed 63% NS1 antigen (nonspecific antigen 1) positivity, and 16% tested positive for both NS1 and IgM (Immunoglobulin M). Symptoms included headache (84%), retroorbital pain (51%), joint pain (75%), myalgia (72%), vomiting (75%), abdominal pain (69%), diarrhea (39%), and shock (48%). Thrombocytopenia was present in 61% of patients, with 79% showing elevated hematocrit (HCT) levels. Pedal edema, pleural effusion, and ascites were observed in DF and DFWS cases, while SD cases exhibited distinct HCT level variations.
Conclusion: Accurate clinical and laboratory assessments are vital for the treatment and prediction of dengue outcomes in Bangladesh, given the severe manifestations of dengue shock syndrome (DSS). It is characterized by headache, muscle pain, thrombocytopenia, anemia, leukopenia, and potential neurological complications or mortality. Severe cases involve critical plasma leakage, leading to DSS with fluid accumulation, respiratory distress, and potential multiorgan involvement. Enhancing physician awareness regarding dengue case detection and management, along with routine dengue testing, are recommended for early diagnosis and improved patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739715 | PMC |
http://dx.doi.org/10.1002/hsr2.70356 | DOI Listing |
Ann Intern Med
January 2025
Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
Ann Intern Med
January 2025
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Neoplasma
December 2024
Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Faculty of Medicine Comenius University, Bratislava, Slovakia.
Pediatric central nervous system (CNS) tumors represent 20-25% of childhood malignancies, with 35-40 new cases annually in Slovakia. Despite treatment advances, high mortality and poor quality of life in a lot of cases persist. This study assesses the clinical features, treatment modalities, and survival rates of pediatric CNS tumor patients in the single largest center in Slovakia.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2-inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation.
View Article and Find Full Text PDFEur J Pediatr
January 2025
Pediatric Oncology and Hematology, Caen University Hospital, Avenue de La Côte de Nacre, 14000, Caen, France.
Unlabelled: Biochemical analyses of cerebrospinal fluid (CSF) are routinely performed at diagnosis in many pediatric oncology and hematology centers when acute leukemia is diagnosed. However, the clinical relevance of these analyses remains unclear. We conducted a retrospective analysis of biochemical CSF data from children diagnosed with acute leukemia at two French hospitals between 2016 and 2023 assessing the results in relation to the presence or absence of leukemic neuromeningeal involvement and the correlation between cytological and biochemical analyses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!